Agios Pharmaceuticals, Inc. - AGIO Quarterly Revenue Growth

Agios Pharmaceuticals (AGIO) - corporate logo

Agios Pharmaceuticals (AGIO) is currently restructuring its business model following the divestment of oncology assets in an effort to diversify its portfolio. The company is recognized as a pioneer in cellular metabolism, having earned the loyalty of patients with rare pathologies. Relative quarterly revenue growth reflects sales dynamics, where 330.30 indicates the value of this parameter. The growth potential of the stock is supported by the expansion of Pyrukynd, incoming royalties, and a significant liquidity reserve.

AGIO Agios Pharmaceuticals Inc Quarterly Sales Growth Rate (07/04/2022 - 11/20/2026)

Summary analytical data breakdowns for Agios Pharmaceuticals, Inc. (AGIO)

- current quotes and average value forecast:
- cash and cash flow indicators:
Comprehensive company analysis:agios.com (AGIO)
Manufactured products of agios.com

For Agios Pharmaceuticals (AGIO), revenue growth reflects the effective commercialization of Pyrukynd and the influx of royalties, allowing for a comparison between actual business scaling rates and market expectations. By analyzing the dynamics of quarterly sales changes, an investor sees a smoothed curve of daily fundamental data recalculations, which helps identify the gap between price euphoria and slowing cash flows, thereby preventing overpayment for the asset.

Competitors of Agios Pharmaceuticals

ASND - Revenue Growth QoQ|MDGL: Revenue Growth QoQ|CORT: Quarterly Revenue Growth|RYTM - Quarterly Sales Growth Rate|Revenue Growth QoQ Akero Corp|Metsera Therapeutics (MTSR) - Quarterly Sales Growth Rate|Revenue Growth QoQ moonlaketx.com (MLTX)|Quarterly Sales Growth Crinetics Pharmaceuticals CRNX|Revenue Growth QoQ NewAmsterdam Pharma N.V. NAMS|Quarterly Sales Growth Rate Soleno Therapeutics Inc (SLNO)|FOLD - Revenue Growth QoQ|ETNB: Revenue Growth QoQ|Structure Therapeutics (GPCR) - Revenue Growth QoQ|Quarterly Sales Growth MiMedx Group, Inc.|Revenue Growth QoQ Rezolute Bio|Lexicon Pharmaceuticals, Inc. (LXRX) - Quarterly Sales Growth Rate|Quarterly Revenue Growth MBX|Quarterly Sales Growth Altimmune, Inc. ALT|Quarterly Revenue Growth AARD (Aardvark Pharma)|Sagimet Biosciences Inc. (SGMT) - Quarterly Revenue Growth Rate|BIOA: Quarterly Sales Growth|Quarterly Revenue Increase BMEA (Biomea Fusion)|QNCX (quincetx.com) - Quarterly Sales Growth|Fractyl - Quarterly Revenue Increase|VTVT (vTv Therapeutics Inc) - Quarterly Revenue Growth|Agape ATP - Revenue Dynamics QoQ|Quarterly Sales Growth PLUR (Pluri Inc)|Quarterly Sales Growth Rate Synlogic Inc.|Revenue Growth QoQ Lipocine Inc. LPCN|Matinas BioPharma (MTNB) - Quarterly Revenue Growth Rate|Spruce Biosciences Inc. - Quarterly Revenue Growth|Quarterly Sales Growth Rate Galecto, Inc. GLTO|Carmell Therapeutics (CTCX) - Revenue Growth QoQ|Lumos Pharma - Quarterly Revenue Increase|ONVO (Organovo Corp) - Quarterly Revenue Growth|Radius Pharmaceuticals (RDUS) - Quarterly Sales Growth Rate